

CURRICULUM VITAE

R. Brian Mitchell, M.D.

rbm@5mitch.net | [804.833.8903](tel:804.833.8903)

June 2022



CURRENT POSITIONS AND ADDRESSES

Virginia Cancer Institute

6605 West Broad Street, Suite A
Richmond, VA 23230
804-287-3000

Mid-Atlantic Medical Consulting, LLC

14241 Midlothian Turnpike, #512
Midlothian, VA 23113
804-833-8903

EDUCATION

1981-85 M.D. Duke University School of Medicine (AOA)

1977-81 A.B. Duke University Degree (Magna cum laude)

POSTGRADUATE TRAINING

1988-92 Fellow in Hematology/Oncology University of Chicago Hospital, Chicago, IL

1985-88 Intern and Resident in Internal Medicine Johns Hopkins Hospital Baltimore, MD

SPECIALTY CERTIFICATION

American Board of Internal Medicine 2008

Subspecialty Certification in Medical Oncology 1991, 2001, 2011

Subspecialty Certification in Hematology 1992, 2002, 2012

MEDICAL LICENSURE

Virginia

ACADEMIC APPOINTMENT

1992-1999 Assistant Professor of Medicine, Department of Medicine, Medical College of Virginia, Virginia Commonwealth University

CLINICAL EXPERIENCE

Locum Tenens work through Hayes Locums February 2018 - present

Clinical Hematology/Oncology Practice with Virginia Cancer Institute, Richmond, VA 1999 - present

Principal, Chest Tumor Center, Henrico Doctor's Hospital, Richmond 2012 - 2017

Academic Clinical Hematology/Oncology Practice at MCV/VCU 1992 - 1999

Attending Physician, Bone Marrow Transplant Unit, MCV/VCU 1992-99

Principal, Chest Tumor Center, MCV/VCU 1992- 1999

MEMBERSHIP IN PROFESSIONAL SOCIETIES

Association of American Physicians and Surgeons 2016 -

American Association for Physician Leadership 2012 - 2015

Richmond Academy of Medicine 1998 -

Virginia Thoracic Society 1995 - 2007

American Society of Hematology 1993 - 2007

International Association for the Study of Lung Cancer 1992 - 2005

American College of Physicians 1989 -

American Association for Cancer Research 1992 - 1997

American Society of Clinical Oncology 1991 -

CLINICAL RESEARCH EXPERIENCE

Chairman, Clinical Trials Review Committee, Massey Cancer Center, VCU, 1993-99

External Grants for Investigator-Initiated Clinical Trials

Hoechst-Roussel Pharmaceuticals, Inc. Grant-in-aid (\$32,200): "A Pilot Study of Pentoxifylline for the Treatment of Cancer Cachexia in Patients with Lung Cancer"

Bristol Myers Squibb Company. (\$8,000): "Biweekly Therapy with Paclitaxel and Carboplatin for Patients with Advanced Non-Small-Cell Lung Cancer" 1997

Alza Pharmaceuticals (\$76,000): "A Pilot Trial of Amifostine to Ameliorate the Toxicities of Paclitaxel/Carboplatin for Patients with Advanced Non-Small-Cell Lung Cancer"

Investigator-Initiated Clinical Trials

Investigator-Initiated clinical trial: A phase I study of a unique schedule of dacarbazine and carmustine, University of Chicago, 1991

A Pilot Study of Pentoxifylline for the Treatment of Cancer Cachexia in Patients with Lung Cancer.

Biweekly Therapy with Paclitaxel and Carboplatin for Patients with Advanced Non-Small-Cell Lung Cancer.

A Pilot Trial of Amifostine to Ameliorate the Toxicities of Paclitaxel/Carboplatin for Patients with Advanced Non-Small-Cell Lung Cancer.

Local Principal Investigator

1994-96 MCV principal investigator, "A Phase II Multicenter Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of DMP 840 Given Every Four Weeks in Patients with Advanced Non-Small Cell Lung Cancer"

1995-97 Investigator, "Effect of Case Management Alternatives on the Satisfaction, Quality of Life, and Cost of Care for End-Stage Metastatic Cancer Patients"

An Open-label, Multicenter, Randomized Phase III, Comparator, Study of Oral Topotecan vs IV Topotecan For Second-Line Therapy in Patients with SCLC Who have Relapsed Greater than or Equal to 90 Days after Completion of First-Line Therapy.

A Randomized Phase 3 Trial of ALIMTA® and Cisplatin versus GEMZAR® and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

SCHOLARLY OR ADMINISTRATIVE EXPERIENCE

Administrative

President and Managing Partner of VCI January 2014 – January 2017

25 providers covering 7 offices and 9 hospitals in 3 cities

Responsible for evaluating entrepreneurial opportunities, setting the strategic direction of the practice, managing physician and employee performance issues, and organizing clinical programs

Management Committee, Virginia Cancer Institute, 2008 – 2017

Laboratory Director, Virginia Cancer Institute Flow Cytometry Laboratory 2015 – 2019

Director of Medical Oncology, Bon Secours St. Mary's Hospital, 2003- 2005
Vice-Chair for Clinical Affairs, Division of Hematology/Oncology, VCU, 1997-99
Coordinator, Outpatient Medical Oncology Services at VCU, 1996-97
Oncology Subcommittee of Pharmacy and Therapeutics Committee, MCV/VCU, 1995-97
Coordinator of Hematology/Oncology Divisional Conferences, 1993-95
Division of Hematology/Oncology Practice Committee, MCV, 1993-95
Internal Medicine Quality Assessment and Improvement Committee, MCV/VCU, 1994-95
Internal Medicine Nurse Practitioner Committee, MCV/VCU, 1994-99

Teaching

Preceptor, Introduction to Clinical Medicine course, MCV/VCU, 1992-96
Hematology Lecture Series, Laboratory Preceptor, MS II, MCV/VCU, 1993-94
Attending Physician, Dalton Hematology/Oncology Clinic, MCV/VCU, 1992-98
Small group discussion leader, Foundations of Clinical Medicine, MCV, 1997-99

OTHER PROFESSIONAL ACTIVITIES

Oncology and Hematology file review with:

Medical Review Institute of America, 2017 – 2019
MES Peer Review 2019 – 2020
Oncology Clinical Case Reviews for MassiveBio, Inc 2018 – 2020
Provider Resources, Inc. 2020-

Medical-Legal consulting 1995 – present

Scientific Reviewer: Medical Care Ombudsman Program, 1994 – 1999

INVITED LECTURES

"Multimodality Modality Treatment of Stage III Lung Cancer"

St. Catherine's Hospital Muncie, Indiana 3/92

"Combined Modality Therapy Using Hyperfractionated Radiotherapy for Esophageal Cancer"

MCV Tumor Board - Concept Review Series, 2/94

"Factor VIII inhibitor"

Medical Grand Rounds (Clinical-Pathologic Conference), MCV, 2/94

"Hematologic Manifestations of Disease"

Annual Spring Institute of the Southside Medical Society, Farmville, Virginia, 4/96

"Combined Modality Therapy of Thoracic Malignancies"

Riverside Hospital Grand Rounds, Newport News, VA, 7/96

"Bronchogenic Carcinoma: The Role of the Oncologist"

Virginia Thoracic Society, Fall Conference, Richmond, VA, 9/29/96

"An Electronic Medical Records System for Oncologists"

Virginia Association of Hematologists & Oncologists, Annual Meeting, Richmond, VA, 10/24/97

"Supportive Care for Patients with Non-Small-Cell Lung Cancer"

1st Annual MCV/VCU Advances in Cancer Therapy, Williamsburg, VA 11/8/97

"Thrombocytopenia and Thrombocytosis"

Grand Rounds Southside Regional Medical Center, Petersburg, VA 12/97

"Combined Modality Therapy for Lung Malignancies"

Oncology Symposium, Rockingham Memorial Hospital, Harrisonburg, VA 11/98

"Advances in Therapy of non-Small Cell Lung Cancer"

Tumor Board Conference, Memorial Regional Medical Center Richmond, VA 9/99

"Cancer Pain"

St. Mary's Hospital Nursing Pain Conference, Richmond, VA 9/29/15

"New Treatments for Cancer & The Promise of Clinical Trials"

Community Cancer Survivor's Symposium, Richmond, VA, 11/7/15

BIBLIOGRAPHY

Original Papers

1. Hunter, R.F., Mold, N.G., Mitchell, R.B., and Huang, A.T.: Differentiation of normal marrow and HL60 cells induced by antithymocyte globulin. Proc. Natl. Acad. Sci. USA, 82: 4823-4827, 1985.
2. Mitchell, R.B., Wagner, J.E., Karp, J.E., et al: Syndrome of idiopathic hyperammonemia after high dose chemotherapy: Review of nine cases. Am J. Med., 85: 662-667, 1988.
3. Dolan, M.E., Stine, L., Mitchell, R.B., Moschel, R.C., and Pegg, A.E.: Modulation of mammalian O⁶-alkylguanine DNA-alkyltransferase in vivo by O⁶-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Communications, 2(11): 371-377, 1990.

4. Dolan, M.E., Mitchell, R.B., Mummert, C., Moschel, R.C., and Pegg, A.E.: Effect of O⁶ benzylguanine analogs on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. *Cancer Res.*, 51: 3367-3372, 1991.
5. Richards, J.M., Gilewski, T.A., Ramming, K.A., Mitchell, B., Doane, L.L., and Vogelzang, N.J.: Effective chemotherapy for melanoma after treatment with interleukin-2. *Cancer*, 69: 427-429, 1992.
6. Mitchell, R.B., Moschel, R.C., and Dolan, M.E.: Effect of O⁶-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis (2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. *Cancer Res.*, 52: 1171-1175, 1992.
7. Mitchell, R.B., and Dolan, M.E.: Effect of temozolomide and dacarbazine on O⁶-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. *Cancer Chemother. Pharmacol.*, 32: 59-63, 1993.
8. Mitchell, R.B., Dolan, M.E., Janisch, L., Vogelzang, N.J., Ratain, M.J., and Schilsky, R.L.: Sequential therapy with dacarbazine and carmustine: A phase I study. *Cancer Chemother Pharmacol*, 34: 509-514, 1994.
9. Mitchell, R.B.: Systemic Therapy for Non-Small-Cell Lung Cancer. *The Virginia Pulmonary Journal*, 3 (2): 1-3, 1997.
10. Mitchell, R.B. and Smith, T.J. Lessons in supportive care, VIII: Having the chart support your goals, and remind you to ask about palliative care. *Clinical Oncology Alert*, February: 14-16, 1998.
11. Roa, V., Conner, A. and Mitchell, R.B.: Carboplatin and paclitaxel for previously treated patients with non small cell lung cancer. *Cancer Investigation*, 26 (6): 381-384, 1998.
12. Hensley, M.L., Schucter, L.M., Lindley, C., et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. *Journal of Clinical Oncology*, 17 (10): 3333-3355, 1999.

Abstracts

1. Richards, J.M., Gilewski, T.A., Doane, L.L., Mitchell, R.B., Ramming, K., and Vogelzang, N.J.: Active chemotherapy for metastatic melanoma following failure of interleukin-2-based therapy. *Proc. Am. Assoc. Cancer Res.*, 31: 199, 1990.
2. Mitchell, R.B., and Dolan, M.E. Enhancement of alkylating agent activity in vitro and in vivo by O⁶-benzylguanine. *Clin. Res.*, 38(3): 843A, 1990.

3. Dolan, M.E., Mitchell, R.B., Moschel, R.C., and Pegg, A.: Effect of O⁶-benzylguanine analogues on O⁶-alkylguanine-DNA alkyltransferase activity and on the sensitivity of cells to alkylating agents. Proc. Amer. Assoc. Cancer Res., 32: 375, 1991.
4. Dolan, M.E., Mitchell, R.B., Moschel, R.C., and Pegg, A.E.: Effect of O⁶-benzylguanine on O⁶-alkylguanine-DNA alkyltransferase activity in vivo and on the sensitivity of human glioma xenografts to chloroethylnitrosoureas. Ninth International Conference on Brain Tumor Research and Therapy, Asilomar, California, 1991.
5. Mitchell, R.B., and Dolan, M.E.: Enhancement of carmustine activity by inhibition of O⁶-alkylguanine-DNA alkyltransferase with dacarbazine or O⁶-benzylguanine. Clin. Res., 39(3): 747A, 1991.
6. Mitchell, R.B., Dolan, M.E., Janisch, L., Ratain, M.J., and Schilsky, R.L. A phase I study of a unique schedule of dacarbazine and carmustine. Proc. Amer. Assoc. Cancer Res., 33: 236, 1992.
7. Mitchell, R.B., Chitre, A.A., and Dolan, M.E. Effect of temozolomide or dacarbazine on the sensitivity of human tumor cells and xenografts to carmustine. Proc. Amer. Assoc. Cancer Res., 33: 485, 1992.
8. Dolan, M.E., Mitchell, R.B., Pegg, A.E., Moschel, R.C., and Grindy, G.B.: Effect of O⁶-benzylguanine on the sensitivity of human tumor xenografts to BCNU. Proc. Amer. Assoc. Cancer Res., 33: 484, 1992.
9. Mitchell, R.B., Goss, G., Guarino, M., Keaton, M., Hammond, N., Ginizio, M., and Gray, J. Phase II trial of bisnafide in advanced non-small cell lung cancer. Proc. Amer. Soc. of Clinical Oncology, 15: 404, 1996.
10. Roa, V., Conner, A., and Mitchell, R.B. Carboplatin and paclitaxel for chemotherapy-naive patients with advanced non-small cell lung cancer. Proc. Amer. Soc. of Clinical Oncology, 15: 404, 1996.
11. Roa, V., Conner, A., and Mitchell, R.B. Carboplatin and paclitaxel for advanced non-small cell lung cancer in previously treated patients. Proc. Amer. Soc. of Clinical Oncology, 15: 403, 1996.
12. Swisher, K.N., Ulmer, D.L., Carpenter, W., Mitchell, R.B., Wan, T.H., Dowdy, M., and Smith, T.J. Patient indemnification as a way to involve patients in economic decision-making about their care: barriers in the current system. Proc. Amer. Soc. of Clinical Oncology, 15: 328, 1996.

13. Mitchell, R.B. A simple computer based clinic note system generates a cumulative record at each visit and saves physician and transcriptionist time. Proceedings ASCO. 16: 425a,1997.
14. Conner, A.C. and Mitchell, R.B. Biweekly carboplatin and paclitaxel for advanced non small cell lung cancer. Proceedings ASCO. 16: 465a, 1997
15. Mitchell, R.B. Amifostine to ameliorate the neurotoxicity of carboplatin/paclitaxel for advanced non-small-cell lung cancer. Proceedings ASCO 17:1998

Book Chapters

1. Mitchell, R.B., Ratain, M.J., and Vogelzang, N.J.: Experimental rationale for continuous infusion chemotherapy. In JJ Lokich, ed: Cancer chemotherapy by infusion. Chicago: Precept Press, Inc., 1990, p. 3-34.
2. Mitchell, R.B., Ratain, M.J., and Vogelzang, N.J.: Experimental rationale for continuous infusion chemotherapy. In M Rotman and CJ Rosenthal, eds: Concomitant continuous infusion chemotherapy and radiation. Berlin: Springer-Verlag, 1991, p. 13-27.
3. Mitchell, R.B., and Hoffman, P.C.: Anemia, leukopenia, and elevated blood counts. In JB Hall, GA Schmidt, and LDH Wood, eds: Principles of Critical Care Medicine. New York: McGraw-Hill Publishing Co., 1992, pp. 1807-1817.
4. Mitchell, R.B., and Hoffman, P.C.: Anemia, leukopenia, and elevated blood counts. In JB Hall, GA Schmidt, and LDH Wood, eds: Principles of Critical Care Medicine, 2nd edition. New York: McGraw-Hill Publishing Co., 1998, pp. 1033-1042.

Editorials

1. Smith, T.J., Hillner, B.E., and Mitchell, R.B. Decision analysis in non-small-cell lung cancer: Not back to the drawing modeling board, back to the bedside. Journal of Clin. Oncol., 15: 870-872, 1997.
2. Smith, T.J. and Mitchell, R.B. The Mather et al Article Reviewed. Oncology 12: 210-216, 1998